| Expression pattern: |
DN |
| Associated gene: |
MAVS, EP300, AGO2, TBK1, IRF3, NFkappaB, P65 |
| Associated microRNA: |
miR-6837-3p |
| Biological function: |
inhibits malignant behaviors (proliferation/colony formation/tumor growth) and promotes antitumor immunity in colorectal cancer |
| Molecular mechanism: |
ceRNA sponging miR-6837-3p to stabilize/upregulate MAVS, activating MAVS-mediated type I IFN signaling (TBK1/IRF3/NFkappaB phosphorylation) and ISG expression; upstream transcriptional regulation by EP300 via RERE promoter |
| Biological pathway or process: |
STING/IFN (promotes); immune regulation (promotes); proliferation (inhibits); ceRNA regulation (promotes) |
| Detected method: |
Q
S
|
| Validation methods: |
circRNA-seq; RNase R Treatment; RT-qPCR; Back-Splice Junction PCR / divergent primers PCR; Sanger Sequencing; Actinomycin D / DRB Stability Assay; Nuclear-Cytoplasmic Fractionation; FISH / smFISH; RNA-seq; RIP (RNA Immunoprecipitation); Luciferase Reporter Assay; RNA Pull-Down; Transfection; CCK8; Colony Formation Assay; Western Blot; IF (Immunofluorescence); ChIP / ChIP-seq; In Vivo Animal Model; Bioinformatics Analysis; Clinical Sample Validation |
| Clinical significance: |
circRERE is underpresented in colorectal cancer tissues and is explored as a gene therapy target (circRERE-AAV) and as a strategy to boost anti-PD-1 immunotherapy efficacy |
| Description: |
In colorectal cancer, circRERE is down-regulated and functions as a tumor suppressor. It sponges miR-6837-3p to increase MAVS, activating MAVS-driven type I IFN signaling and enhancing antitumor immunity; EP300 promotes circRERE transcription via the RERE promoter. AAV-mediated circRERE delivery suppresses tumor growth and sensitizes anti-PD-1 therapy in mouse models. |
| Confidence score: |
0.8644 |